Skip to main content
Caplight Logo









Sartar Therapeutics

Sartar Therapeutics

Private
HelsinkiHealthcare & Life Scienceshttps://www.sartartherapeutics.com/

Last Round

Early Funding

Oct 1, 2025

Est. Valuation

$15.59M

Total Funding Raised

$9.36M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Sartar Therapeutics is a pharmaceutical company that develops precision cancer treatments for gastrointestinal stromal tumors and other soft tissue sarcomas.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverymolecular glueprecision medicinegastrointestinal stromal tumorsGISTdrug repurposingsoft tissue sarcomatargeted cancer therapyorphan drugpreclinical researchbiotech startuponcology pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sartar Therapeutics Comparables

Compare Sartar Therapeutics with similar companies based on industry and business-model similarity.

Sartar Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GSK plc
74%
Amira Therapeutics
74%
Degron Therapeutics
72%

Sartar Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingOct 1, 2025
DebtSep 20, 2021
SeedOct 19, 2020

Key People

Founding team and executive leadership

Mikael Maksimow

Chief Executive Officer

Executive Team

Sartar Therapeutics Investors

Notable investors and investment history

Sartar Therapeutics investors
InvestorRounds
Excedea CapitalEarly Funding
Business FinlandDebt
Health Incubator HelsinkiSeed
NOMESeed
SpringvestEarly Funding, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Monthly visitors grew 961% MoM, from 67 to 711.

  • Feb 14, 2026

    Grew 75% QoQ from 4 to 7 employees.

Sartar Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sartar Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sartar Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHelsinki
Employee Range7
Year Founded2016
Last FundingOct 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?